US investor to buy U. Dori stake

Under the terms of the agreement, Dembitzer will provide the U. Dori Group with a $31 million owners loan for the Acad shares. Uri Dori will use $19 million of the proceeds to buy out the 33% stake in Acad held by Amethyst, owned by Ronen Kristal.

By SHARON WROBEL
September 11, 2006 09:27

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Acad Building & Investments Ltd. has signed a memorandum of understanding with Alex Dembitzer, owner of New York-based Northern Group Inc., under which he will acquire half of Acad's 90 per cent stake in the U. Dori Group, the real estate and development enterprise. The other half will stay in the ownership of Uri Dori, president of the U. Dori Group. Under the terms of the agreement, Dembitzer will provide the U. Dori Group with a $31 million owners loan for the Acad shares. Uri Dori will use $19 million of the proceeds to buy out the 33% stake in Acad held by Amethyst, owned by Ronen Kristal.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS